New research has shown that neuroendocrine tumors are more common than previously thought.  Progress in our understanding of the molecular pathogenesis of these not-so-rare cancers has resulted in renewed interest in developing innovative therapeutic options.  In particular, novel molecular targeted agents have been shown to have significant anti-tumor activity, and integration of these therapies has led to critical advances in management.